A cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic evaluation alongside the REaCT-G trial

被引：0
|
作者：
Basulaiman, B. [1 ,2 ]
Awan, A. A. [1 ,2 ]
Hilton, J. [1 ,2 ]
Fergusson, D. [3 ]
Stober, C. [2 ,4 ]
Vandermeer, L. [2 ,4 ]
Saunders, D. [2 ,4 ]
Clemons, M. [1 ,2 ]
Thavorn, K. [3 ]
机构：
[1] Ottawa Hosp, Div Med Oncol, Dept Med, Ottawa, ON, Canada
[2] Univ Ottawa, Ottawa, ON, Canada
[3] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[4] Ottawa Hosp Res Inst, Canc Res Grp, Ottawa, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A multicentre, randomised trial comparing schedules of G-CSF ( fi lgrastim) administration for primary prophylaxis of chemotherapy -induced febrile neutropenia in early stage breast cancer
    Clemons, M.
    Fergusson, D.
    Simos, D.
    Mates, M.
    Robinson, A.
    Califaretti, N.
    Zibdawi, L.
    Bahl, M.
    Raphael, J.
    Ibrahim, M. F. K.
    Fernandes, R.
    Pitre, L.
    Aseyev, O.
    Stober, C.
    Vandermeer, L.
    Saunders, D.
    Hutton, B.
    Mallick, R.
    Pond, G. R.
    Awan, A.
    Hilton, J.
    ANNALS OF ONCOLOGY, 2020, 31 (07) : 951 - 957
  • [2] Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles
    van Dooijeweert, C.
    van der Wall, E.
    Baas, I. O.
    NETHERLANDS JOURNAL OF MEDICINE, 2019, 77 (09): : 310 - 316
  • [3] The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis
    Hutajulu, Susanna Hilda
    Oktariani, Siswi
    Sunggoro, Agus Jati
    Bintoro, Bagas Suryo
    Astari, Yufi Kartika
    Wiranata, Juan Adrian
    Widodo, Irianiwati
    Ekowati, Anita
    Hardianti, Mardiah Suci
    Taroeno-Hariadi, Kartika Widayati
    Kurnianda, Johan
    Purwanto, Ibnu
    ECANCERMEDICALSCIENCE, 2023, 17
  • [4] Febrile neutropenia in FEC-D regimen for early stage breast cancer, is there a place for G-CSF primary prophylaxis?
    Miguel, I.
    Wincler, P.
    Sousa, M.
    Cardoso, C.
    Moreira, A.
    Brito, M.
    CANCER RESEARCH, 2013, 73
  • [5] History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis
    Chao, C.
    Page, J. H.
    Yang, S. -J.
    Rodriguez, R.
    Huynh, J.
    Chia, V. M.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1821 - 1829
  • [6] Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
    T. Younis
    D. Rayson
    S. Jovanovic
    C. Skedgel
    Breast Cancer Research and Treatment, 2016, 159 : 425 - 432
  • [7] Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia
    James A. Chiarotto
    George Dranitsaris
    Supportive Care in Cancer, 2013, 21 : 2727 - 2731
  • [8] Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
    Younis, T.
    Rayson, D.
    Jovanovic, S.
    Skedgel, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 425 - 432
  • [9] Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia
    Chiarotto, James A.
    Dranitsaris, George
    SUPPORTIVE CARE IN CANCER, 2013, 21 (10) : 2727 - 2731
  • [10] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    CANCER RESEARCH, 2013, 73
12345